Study on the of Anagrelide on Platelet Factor 4 and Vascular Endothelial Growth Factor Levels in Patients with Essential Thrombocythemia

The myeloproliferative neoplasm Essential Thrombocythemia (ET) is characterised by a high platelet count and platelet activation connected to angiogenesis. Platelet activation is promoted by vascular endothelial growth factor (VEGF), and active platelets emit VEGF, according to research. Anagrelide (ANA) is a new medication that lowers platelet counts and inhibits platelet activation. Platelet count, platelet factor…
Read more

October 19, 2021 0